v3.26.1
SEGMENT AND ENTERPRISE-WIDE INFORMATION
 3 Months Ended
Jun. 27, 2026
Segment Reporting [Abstract]  
SEGMENT AND ENTERPRISE-WIDE INFORMATION
16. SEGMENT AND ENTERPRISE-WIDE INFORMATION
On June 5, 2026, the Company implemented an organizational realignment designed to align its commercial operations into two global reportable segments by combining the previously reported Plasma and Blood Center reportable segments into Apheresis and renaming the Hospital reportable segment to MedSurg. This organizational structure reflects how the Company is organized to manage operations, allocate resources and evaluate performance. As a result, the information that is regularly reviewed by the Company’s chief operating decision maker (“CODM”), identified as the Chief Executive Officer, has changed. Prior-period segment information presented has been recast to reflect the current reportable segment structure.
The Company’s reportable and operating segments are as follows:
•Apheresis
•MedSurg
The CODM measures and evaluates the operating segments based on operating income for purposes of assessing business performance and allocating resources. The CODM uses segment operating income for each segment by comparing on a quarterly basis actual results to the prior year comparable period and to the annual operating plan to assess the performance of the segments and to allocate resources across our segments. Certain corporate expenses and amounts considered to be non-recurring or non-operational are excluded from segment operating income. These items include restructuring costs, restructuring related costs, digital transformation costs, amortization of acquired intangible assets, amortization of fair value inventory step-up, acquisition, integration and divestiture related costs, unusual or infrequent and material litigation-related charges, and remeasurement of contingent consideration. Although these amounts are excluded from segment operating income, as applicable, they are included in the reconciliations that follow.
The Company does not track its total assets by segment. Consequently, the Company’s CODM does not review total assets by segment when assessing business performance and allocating resources.
Selected information by reportable segment is presented below:
Three Months Ended
June 27, 2026June 28, 2025
(Dollars in Thousands)
Net revenues:
Apheresis$191,318 $181,736 
MedSurg148,062 139,658 
Total net revenues$339,380 $321,394 
Significant segment expenses and operating performance:
Apheresis
Cost of goods sold$84,131 $75,865 
Selling, general and administrative44,264 39,880 
Research and development6,378 6,816 
Apheresis operating income$56,545 $59,175 
MedSurg
Cost of goods sold$50,368 $50,216 
Selling, general and administrative65,160 62,323 
Research and development9,820 8,742 
MedSurg operating income$22,714 $18,377 
Corporate and unallocated expenses
Amortization of acquired assets$(10,204)$(13,828)
Integration and transaction costs(2,719)(2,682)
Restructuring and restructuring related costs(2,258)(1,324)
Digital transformation costs(6,163)(5,355)
Other(1)
(457)(491)
Operating income57,458 53,872 
Interest and other expense, net(9,884)(8,703)
Income before provision for income taxes$47,574 $45,169 
__________
(1)    Comprised of litigation-related charges and remeasurement of contingent consideration for the three months ended June 27, 2026 and June 28, 2025.
Net revenues by business unit are as follows:
Three Months Ended
June 27, 2026June 28, 2025
(Dollars in Thousands)
Apheresis
Plasma$155,524 $145,074 
Other35,794 36,662 
Apheresis net revenues$191,318 $181,736 
MedSurg
Interventional Technologies$59,942 $58,483 
Blood Management Technologies88,120 81,175 
MedSurg net revenues$148,062 $139,658 
Total net revenues$339,380 $321,394 
Depreciation and amortization, excluding impairment charges, by business unit are as follows:
Three Months Ended
June 27, 2026June 28, 2025
(Dollars in Thousands)
Apheresis$13,631 $13,912 
MedSurg13,480 14,846 
Total depreciation and amortization (excluding impairment charges)$27,111 $28,758 
Long-lived assets, comprised of property, plant and equipment, by business unit are as follows:
June 27, 2026March 28,
2026
(Dollars in Thousands)
Apheresis$244,089 $246,042 
MedSurg59,689 59,719 
Total long-lived assets$303,778 $305,761 
Long-lived assets, comprised of property, plant and equipment, by operating regions are as follows:
June 27, 2026March 28,
2026
(Dollars in Thousands)
United States$223,004 $224,699 
Japan882 916 
Europe32,293 32,080 
Rest of Asia30,010 30,833 
Other17,589 17,233 
Total long-lived assets$303,778 $305,761 
Net revenues by operating regions are as follows:
Three Months Ended
June 27, 2026June 28, 2025
(Dollars in Thousands)
United States$257,844 $242,404 
Japan12,858 13,648 
Europe45,529 40,882 
Rest of Asia20,163 21,648 
Other2,986 2,812 
Total net revenues$339,380 $321,394